The second point is that, unlike some antidiabetic drugs such as SGLT‐2 inhibitors or GLP‐1 receptor agonists, which have been demonstrated to have special mechanisms to improve cardiovascular outcomes, GK activators build their efficacy directly on the recovery of GK target to achieve ideal glucose control, which may have stronger protective effects on coronary artery disease and heart failure than nontargeted glucose‐lowering regimens.61 The gene discussed is GLP1R; the disease is heart failure.